Biotech Values

[DewDiligence]

SNY pulls Semuloparin MAA:

http://in.reuters.com/article/2012/07/09/us-sanofi-ema-idINBRE8680M920120709?feedType=RSS&feedName=health&utm_source=dlvr.it&utm_medium=twitter&dlvrit=309303

Pulling an application is SOP in the EU when regulators have concluded that a rejection is imminent. Given today’s news and the rejection of Semuloparin by an FDA advisory panel in June (#msg-76811758), it’s reasonable to presume that this drug is effectively dead.

Semuloparin, an ultra-LMW heparin, is also knows as Mulsevo, Visamerin, and AVE5026. It was once touted as SNY’s follow-on product to Lovenox.